JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

MDT

102.96

+1.98%↑

133.74

+0.46%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

MDT

102.96

+1.98%↑

133.74

+0.46%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

MDT

102.96

+1.98%↑

133.74

+0.46%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

MDT

102.96

+1.98%↑

133.74

+0.46%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

MDT

102.96

+1.98%↑

133.74

+0.46%↑

Kodu・Aktsiate loetelu・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Suletud

SektorTervishoid

41.05 -1.82

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

40.25

Max

41.75

Põhinäitajad
By Trading Economics
Sissetulek	-6.2M -91M
Kasumimarginaal	-867.293
Töötajad	316
EBITDA	4M -90M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+28.94% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	26. veebr 2026

Turustatistika
By TradingEconomics
Turukapital	31M 3.3B
Eelmine avamishind	42.87
Eelmine sulgemishind	41.05

Uudiste sentiment

By Acuity

50%

148 / 352 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

34.81 / 38.24 Toetus ja vastupanu

Xenon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

30. jaan 2026, 20:14 UTC

Omandamised, ülevõtmised, äriostud

Reddy Ice to Buy Arctic Glacier, DOJ Requires Certain Divestitures

30. jaan 2026, 23:47 UTC

Omandamised, ülevõtmised, äriostud

Negotiations Over $100B OpenAI, Nvidia Deal Stall -- WSJ

30. jaan 2026, 23:47 UTC

Omandamised, ülevõtmised, äriostud

Nvidia, OpenAI in Talks to Revise Nature of Broader Partnership, Sources Say -- WSJ

30. jaan 2026, 23:47 UTC

Omandamised, ülevõtmised, äriostud

Nvidia CEO Jensen Huang Has Privately Told Colleagues That Deal Is Non-Binding, Sources Say -- WSJ

30. jaan 2026, 23:47 UTC

Omandamised, ülevõtmised, äriostud

Nvidia's Huang Has Privately Criticized OpenAI's Business Strategy, Sources Say -- WSJ

30. jaan 2026, 23:47 UTC

Omandamised, ülevõtmised, äriostud

OpenAI, Nvidia Deal Talks Stalled in Recent Months, Sources Say -- WSJ

30. jaan 2026, 23:47 UTC

Omandamised, ülevõtmised, äriostud

Nvidia's Huang Expressed Concerns Over Competition OpenAI Faces From Anthropic, Google, Sources Say -- WSJ

30. jaan 2026, 23:47 UTC

Omandamised, ülevõtmised, äriostud

Nvidia Weighing Equity Investment of Tens of Billions of Dollars Into OpenAI, Sources Say -- WSJ

30. jaan 2026, 23:47 UTC

Omandamised, ülevõtmised, äriostud

Negotiations Over $100B OpenAI, Nvidia Deal Stall, Sources Say -- WSJ

30. jaan 2026, 23:41 UTC

Market Talk

Deckers Outdoor Seen as Undervalued -- Market Talk

30. jaan 2026, 23:12 UTC

Omandamised, ülevõtmised, äriostud

Supreme Court of British Columbia Approves Fortescue Purchase of Alta Copper

30. jaan 2026, 22:20 UTC

Tulu

Verizon Posts Strong Subscriber Gains Under New CEO -- WSJ

30. jaan 2026, 22:10 UTC

Market Talk

Disney CEO's Exit Plan Marks Abrupt End to Messy Succession -- Market Talk

30. jaan 2026, 21:50 UTC

Market Talk

Tulu

Tech, Media & Telecom Roundup: Market Talk

30. jaan 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

30. jaan 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

30. jaan 2026, 21:42 UTC

Tulu

These Stocks Are Today's Movers: Apple, Verizon, SoFi, Sandisk, Western Digital, Unity Software, Exxon, and More -- Barrons.com

30. jaan 2026, 21:36 UTC

Tulu

GE Aerospace and GE Vernova Issue Their Annual Reports. They Contain Messages for Investors. -- Barrons.com

30. jaan 2026, 21:33 UTC

Tulu

Tesla Stock Rebounds From Earnings Dip. SpaceX Is Helping. -- Barrons.com

30. jaan 2026, 20:42 UTC

Tulu

These Stocks Are Today's Movers: Apple, Verizon, SoFi, Sandisk, Western Digital, Unity Software, Exxon, and More -- Barrons.com

30. jaan 2026, 20:37 UTC

Omandamised, ülevõtmised, äriostud

Why a Ruling Over CK Hutchison's Panama Canal Ports Matters -- and What's Next -- WSJ

30. jaan 2026, 20:20 UTC

Market Talk

Oil Posts Weekly Gains on U.S.-Iran Tensions -- Market Talk

30. jaan 2026, 20:13 UTC

Market Talk

U.S. Natural Gas Futures Rise on Weather-Driven Demand -- Market Talk

30. jaan 2026, 19:52 UTC

Tulu

Visa and Amex Results Point to a Strong Holiday Season for Retailers -- Barrons.com

30. jaan 2026, 19:29 UTC

Market Talk

Tulu

KLA Guidance Only 'Tepid' as Memory Rally Favors Peers -- Market Talk

30. jaan 2026, 19:09 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

30. jaan 2026, 19:09 UTC

Market Talk

Next Canadian Inflation Release Pushed Back a Day to Not Clash With Holiday -- Market Talk

30. jaan 2026, 19:07 UTC

Market Talk

Canada Performing Well Below Economic Potential -- Market Talk

30. jaan 2026, 18:46 UTC

Tulu

'All Boats Are Rising' in Data and Memory, Says Western Digital's CFO. Just Look at the Stocks. -- Barrons.com

30. jaan 2026, 18:34 UTC

Tulu

Exxon, Chevron Post Slimmest Annual Profits Since 2021 -- 2nd Update

Võrdlus sarnastega

Hinnamuutus

Xenon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

28.94% tõus

12 kuu keskmine prognoos

Keskmine 54.09 USD 28.94%

Kõrge 62 USD

Madal 44 USD

Põhineb 14 Wall Streeti analüütiku instrumendi Xenon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

14 ratings

Osta

Hoia

Müü

Põhineb 14 analüütiku instrumendi Xenon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

34.81 / 38.24Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

148 / 352 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.